Wolfgang Hammerschmidt Selected Research

Infections

12/2023	Fully Human Herpesvirus-Specific Neutralizing IgG Antibodies Generated by EBV Immortalization of Splenocytes-Derived from Immunized Humanized Mice.
10/2023	SARS-CoV-2 and Epstein-Barr Virus-like Particles Associate and Fuse with Extracellular Vesicles in Virus Neutralization Tests.
11/2022	Structural basis of DNA methylation-dependent site selectivity of the Epstein-Barr virus lytic switch protein ZEBRA/Zta/BZLF1.
5/2022	Quantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic test.
10/2021	Modulation of alternative splicing during early infection of human primary B lymphocytes with Epstein-Barr virus (EBV): a novel function for the viral EBNA-LP protein.
1/2021	Multiple Viral microRNAs Regulate Interferon Release and Signaling Early during Infection with Epstein-Barr Virus.
1/2021	Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection.
1/2020	PD-1 Blockade Aggravates Epstein-Barr Virus+ Post-Transplant Lymphoproliferative Disorder in Humanized Mice Resulting in Central Nervous System Involvement and CD4+ T Cell Dysregulations.
1/2019	First Days in the Life of Naive Human B Lymphocytes Infected with Epstein-Barr Virus.
1/2019	Spatiotemporally Skewed Activation of Programmed Cell Death Receptor 1-Positive T Cells after Epstein-Barr Virus Infection and Tumor Development in Long-Term Fully Humanized Mice.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wolfgang Hammerschmidt Research Topics

Disease

20	Infections 12/2023 - 09/2002
14	Neoplasms (Cancer) 09/2020 - 09/2003
11	Epstein-Barr Virus Infections 02/2023 - 04/2004
5	Lymphoma (Lymphomas) 01/2020 - 07/2004
3	Latent Infection 01/2019 - 01/2012
3	Carcinogenesis 03/2014 - 11/2007
2	COVID-19 05/2022 - 01/2022
2	Virus Diseases (Viral Diseases) 01/2022 - 01/2021
2	Inflammation (Inflammations) 09/2020 - 10/2012
2	Hodgkin Disease (Hodgkin's Disease) 12/2005 - 07/2004
2	Burkitt Lymphoma (Burkitt's Lymphoma) 12/2005 - 08/2005
1	Porcine Reproductive and Respiratory Syndrome (PRRS) 01/2022
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2020
1	Leukemia 01/2020
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2020
1	Residual Neoplasm 01/2020
1	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2020
1	Viremia 01/2019
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2011
1	B-Cell Lymphoma (Lymphoma, B Cell) 12/2005
1	Communicable Diseases (Infectious Diseases) 07/2005

Drug/Important Bio-Agent (IBA)

8	Proteins (Proteins, Gene)FDA Link 10/2021 - 09/2003
5	MicroRNAs (MicroRNA)IBA 01/2022 - 10/2012
5	Viral ProteinsIBA 09/2020 - 08/2003
5	Epstein-Barr Virus Nuclear AntigensIBA 08/2005 - 08/2003
4	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 09/2002
4	AntigensIBA 01/2019 - 07/2005
3	AntibodiesIBA 12/2023 - 07/2004
3	Viral DNAIBA 01/2021 - 01/2010
2	Neutralizing AntibodiesIBA 10/2023 - 05/2022
2	VaccinesIBA 02/2023 - 01/2020
2	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 11/2022 - 03/2014
2	Monoclonal AntibodiesIBA 05/2022 - 01/2020
2	InterferonsIBA 01/2022 - 01/2021
2	Messenger RNA (mRNA)IBA 10/2021 - 05/2012
2	Transcription Factors (Transcription Factor)IBA 01/2020 - 03/2014
2	ChromatinIBA 01/2019 - 01/2015
2	Membrane Proteins (Integral Membrane Proteins)IBA 11/2007 - 12/2005
1	EnzymesIBA 10/2023
1	A-Form DNA (A-DNA)IBA 11/2022
1	N-(2-cyanoethylene)urea (BA 1)IBA 05/2022
1	Pattern Recognition ReceptorsIBA 01/2022
1	Viral AntigensIBA 01/2022
1	Immunoglobulin G (IgG)IBA 01/2022
1	Nucleocapsid ProteinsIBA 01/2022
1	LigandsIBA 10/2021
1	Interferon Type IIBA 01/2021
1	Antiviral Agents (Antivirals)IBA 01/2021
1	RibonucleoproteinsIBA 01/2021
1	Oncogene Proteins (Oncogene Protein)IBA 01/2021
1	CD40 Ligand (CD40L)IBA 01/2021
1	Abatacept (Orencia)FDA Link 01/2020
1	pembrolizumabIBA 01/2020
1	Death Domain ReceptorsIBA 01/2020
1	Immune Checkpoint InhibitorsIBA 01/2020
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2019
1	Nuclear Antigens (Extractable Nuclear Antigens)IBA 01/2019
1	Firefly LuciferasesIBA 01/2019
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 05/2014
1	TensinsIBA 05/2014
1	CytokinesIBA 05/2012
1	RNA (Ribonucleic Acid)IBA 05/2012
1	5-Methylcytosine (5 Methylcytosine)IBA 01/2012
1	CytosineIBA 01/2010
1	GuanosineIBA 01/2010
1	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 12/2005
1	ProteomeIBA 04/2004

Therapy/Procedure

2	Immunotherapy 01/2011 - 01/2008
1	Cell- and Tissue-Based Therapy (Cell Therapy) 09/2020
1	Drug Therapy (Chemotherapy) 01/2020
1	Stem Cell Transplantation 01/2020
1	Transplantation 12/2005